OBJECTIVE： To investigate the effects of intensive atorvastatin therapy on postoperative blood lipid， inflammation reaction and major adverse cardiac events （MACE） in non-ST segment elevation myocardial infarction （NSTEMI） patients before PCI. METHODS： A total of 120 NSTEMI patients underwent selective PCI were randomly divided into control group （60 cases） and observation group （60 cases）. Both groups were given Aspirin enteric-coated tablet 0.3 g orally， once a day+Clopidogrel sulfate tablet 300 mg orally， once a day， immediately after admission. After operation， they were given medicine continuously for consecutive 12 weeks. Control group was given Atorvastatin calcium tablet 80 mg orally， immediately after operation， and then was given 40 mg， once a day， for consecutive 12 weeks. Observation group was additionally given Atorvastatin calcium tablet 40 mg orally 6 h before operation on the basis of control group. The levels of TG， TC， HDL-C， LDL-C， hs-CRP， TNF-α and IL-10 before and after PCI， the incidence of postoperative MACE， postoperative re-hospitalization rate and the occurrence of ADR were observed in 2 groups. RESULTS： There was no statistical significance in the levels of TG， TC， HDL-C or LDL-C between 2 groups before and after operation （P＜0.05）. After operation， the levels of hs-CRP， TNF-α and IL-10 in 2 groups were significantly higher than before operation， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of postoperative MACE， postoperative re-hospitalization rate or the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Intensive atorvastatin therapy before PCI can effectively reduce the levels of inflammatory response in NSTEMI patients， but have no significant changes in blood lipid levels and MACE risk， without increasing the incidence of ADR.